Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising results in preliminary patient assessments . Recent https://maximusbookmarks.com/story21444650/retatrutide-emerging-investigations-and-possible-medical-roles